Additional Information

Description

Actemra 400 mg/20 mL Single-Dose Vial contains tocilizumab, a recombinant humanized monoclonal antibody that specifically targets the interleukin-6 (IL-6) receptor. By inhibiting IL-6 signaling, it reduces inflammation and immune system overactivity. It is indicated for the treatment of rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.

The formulation is supplied as a sterile, preservative-free solution in a single-dose vial for intravenous (IV) infusion or subcutaneous injection, depending on the condition being treated. Administration should be performed under medical supervision due to the risk of serious hypersensitivity reactions.

Common adverse effects include infections, infusion-related reactions, elevated liver enzymes, neutropenia, and gastrointestinal symptoms. Serious risks include severe infections, gastrointestinal perforation, hepatotoxicity, and demyelinating disorders. Routine monitoring of liver function, neutrophil counts, and lipid profiles is required to minimize complications.